Author(s):
Yasir SJ. Alrubaye, Mohammed BM. Al-Juboori, Ameer K. Al-Humairi
Email(s):
mbm.research.86@gmail.com , ph.yasiralrubaye@gmail.com , mbm.clinical.86@gmail.com , ameer.alhumairi@gmail.com
DOI:
10.5958/0974-360X.2021.00134.7 
Address:
Yasir SJ. Alrubaye1, Mohammed BM. Al-Juboori1*, Ameer K. Al-Humairi2
1Assistant Lecturer, Department of Therapeutic and Clinical Pharmacy, Baghdad College of Medical Sciences, Baghdad-Iraq.
2Assistant Professor-Department of Community Medicine, College of Medicine, Babylon University, Babylon-Iraq.
*Corresponding Author
Published In:
Volume - 14,
Issue - 2,
Year - 2021
ABSTRACT:
Background: Rheumatoid arthritis (RA) is a chronic progressive autoimmune inflammatory systemic disease; methotrexate is the first drug of choice to retard the disease progression. Objective: To elucidate the main factors that leading to non-adherence to methotrexate in patients with rheumatoid arthritis. Method: In this cross-sectional study, one hundred twenty-two (122) patients diagnosed with RA = 18 years old on methotrexate (mono or combined therapy) for at least three months. Data were recorded including demographic data, socioeconomic status, education level, disease duration, duration of methotrexate therapy, current weekly methotrexate dose, concomitant drugs, and factors might contribute to non-adherence. Non-adherence was considered when three or more of weekly dose of methotrexate were omitted in the last 8 weeks. Results: 38 patients (31.14%) were non-adherent. Patients with longer disease duration, those with higher education level, and on concomitant steroid had higher rate of non-adherence. Among the factors contributing to non-adherence are: Methotrexate Don’t treat arthritis symptoms well 25 patients (65.78%), social myths 24 patients (63.15%), Don’t need it when feeling well: 22 patients (57.89%) were on the top of list. Conclusion: The patients with non-adherence in the current study constitute about one third of the patients. Good adherence rate can increase by good doctor-patients communication and continuous patients’ education and counseling by treating rheumatologist.
Cite this article:
Yasir SJ. Alrubaye, Mohammed BM. Al-Juboori, Ameer K. Al-Humairi. The Causes of Non-Adherence to Methotrexate in patients with Rheumatoid Arthritis. Research J. Pharm. and Tech. 2021; 14(2):769-774. doi: 10.5958/0974-360X.2021.00134.7
Cite(Electronic):
Yasir SJ. Alrubaye, Mohammed BM. Al-Juboori, Ameer K. Al-Humairi. The Causes of Non-Adherence to Methotrexate in patients with Rheumatoid Arthritis. Research J. Pharm. and Tech. 2021; 14(2):769-774. doi: 10.5958/0974-360X.2021.00134.7 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-2-30
REFERENCES:
1. Venkataramanan R V, Sumithra M. A complete review on Rheumatoid arthritis and Diabetes Mellitus – A Unknown Connection. Research J. Pharm. and Tech 2018; 11(11): 5212-5218.
2. Srivastava S, Patel S, Daharwal SJ, Singh D, Singh M. Rheumatoid Arthritis: An Autoimmune Disease Prevalent in Females. Research J. Pharm. and Tech. 9(2): Feb., 2016; Page 170-172.
3. Muss TQ, AL-Faham M, Gorial FI, Zghair AK. Galectin-8 Gene Polymorphism among Iraqi Patients with Rheumatoid Arthritis. Research J. Pharm. and Tech. 2019; 12(4):1643-1645
4. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39.
5. Nandgude TD, Hasabe PS, Kolsure AK. Clinical Features and Treatment of Rheumatoid Arthritis: A Review. Research J. Pharm. and Tech 2018; 11(12): 5701-5706.
6. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977.
7. Mulla JA, Suresh S, Khazi IA. Formulation, Characterization and in vitro Evaluation of Methotrexate Solid Lipid Nanoparticles. Research J. Pharm. and Tech.2 (4): Oct.-Dec. 2009; Page 685-689.
8. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9(10):249–262.
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.
10. Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58(5):1310-7.
11. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002;288: 2868-79.
12. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007 Jun;7(6):429-42.
13. Premkuma B. Antioxidant Defense and Disease activity in Rheumatoid Arthritis. Research J. Pharm. and Tech 2018; 11(5):1810-1814.
14. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762-84.
15. Chatzidionysiou K, Sfikakis PP. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019;5(2): e000993.
16. Kotadiya RM, Patel VA, Patel HV. Factorial Design Based Formulation and Characterization of the Controlled Release Methotrexate Beads. Research J. Pharm. and Tech.2 (3): July-Sept. 2009,; Page 592-596.
17. Elliott RA. Poor adherence to medication in adults with rheumatoid arthritis: Reasons and solutions. Disease Management and Health Outcomes, 2008;16(1), 13–29.
18. Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. J Rheumatol. 2016;43(11):1997-2009.
19. Navarro-Millán I, Chen L, Greenberg JD, Pappas DA, Curtis JR. Predictors and persistence of new-onset clinical remission inrheumatoid arthritis patients. Semin Arthritis Rheum 2013;43: 137-43.
20. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS,Anderson JD, et al. Remission of rheumatoid arthritis in clinicalpractice: application of the American College of Rheumatology/European League Against Rheumatism 2011remission criteria. Arthritis Rheum 2011;63: 3204-15.
21. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155–159.
22. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. van den Bemt BJ, Zwikker HE, van den Ende CH. Expert Rev Clin Immunol. 2012 May;8(4):337-51.
23. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11: 44-7.
24. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res. 2011;63(12):1680–1690.
25. van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009 Oct;36(10):2164-70.
26. Arshad N, Ahmad NM, Saeed MA, Khan S, Batool S, Farman S. Adherence to Methotrexate therapy in Rheumatoid Arthritis. Pak J Med Sci. 2016;32(2):413–417.
27. DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey. Rheumatol Ther. 2015;2(1):73–84.
28. Kumar SS, Bhosle D, Janghel A, Deo S, Raut P, Verma C, Agrawal M, Amit N, Sharma M, Giri, D. K. Tripathi1, Ajazuddin, Alexander A. Indian Medicinal Plants Used for Treatment of Rheumatoid Arthritis. Research J. Pharm. and Tech. 8(5): May, 2015; Page 597-610
29. O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2010;69(10):1823-6.
30. Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67(5):624-32.
31. Kumar P. V, Vara Prasanna, P. Shanmugasundaram. A Prospective Study on Comparing the efficacy of Combination Therapy and Monotherapy of DMARDs in Patients with Rheumatoid Arthritis. Research J. Pharm. and Tech 2018; 11(10): 4497-4501.
32. Sandhya Lekshmi S, Antony R, Sidharthan N, Kammath G, Anila KN. Methotrexate Induced Lung Toxicity- A Case Report. Research J. Pharm. and Tech 2017; 10(10):3458-3460.